140 related articles for article (PubMed ID: 29926012)
1. Randomized Phase II Study Comparing Mannitol with Furosemide for the Prevention of Renal Toxicity Induced by Cisplatin-based Chemotherapy with Short-term Low-volume Hydration in Advanced Non-small Cell Lung Cancer: The OLCSG1406 Study Protocol.
Makimoto G; Ichihara E; Hotta K; Ninomiya K; Oze I; Minami D; Ninomiya T; Kubo T; Ohashi K; Tabata M; Maeda Y; Kiura K
Acta Med Okayama; 2018 Jun; 72(3):319-323. PubMed ID: 29926012
[TBL] [Abstract][Full Text] [Related]
2. Randomized study comparing mannitol with furosemide for the prevention of cisplatin-induced renal toxicity in non-small cell lung cancer: The OLCSG1406 trial.
Makimoto G; Hotta K; Oze I; Ninomiya K; Nakanishi M; Hara N; Kano H; Watanabe H; Hata Y; Nishii K; Nakasuka T; Itano J; Ninomiya T; Kubo T; Ohashi K; Ichihara E; Minami D; Sato A; Tabata M; Maeda Y; Kiura K
Asia Pac J Clin Oncol; 2021 Feb; 17(1):101-108. PubMed ID: 32885583
[TBL] [Abstract][Full Text] [Related]
3. Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial.
Murakami E; Akamatsu H; Shimokawa T; Wada K; Yamamoto N
BMJ Open; 2019 Dec; 9(12):e029057. PubMed ID: 31831529
[TBL] [Abstract][Full Text] [Related]
4. A retrospective evaluation of furosemide and mannitol for prevention of cisplatin-induced nephrotoxicity.
Mach CM; Kha C; Nguyen D; Shumway J; Meaders KM; Ludwig M; Williams-Brown MY; Anderson ML
J Clin Pharm Ther; 2017 Jun; 42(3):286-291. PubMed ID: 28276070
[TBL] [Abstract][Full Text] [Related]
5. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
6. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
Dana R; Kachhwaha VS
Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
Cornelison TL; Reed E
Gynecol Oncol; 1993 Aug; 50(2):147-58. PubMed ID: 8375728
[TBL] [Abstract][Full Text] [Related]
8. Comparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
Takagi A; Miyoshi T; Hayashi T; Koizumi H; Tsumagari K; Yokota C; Nakano T; Matsuo K; Egawa T
Sci Rep; 2024 May; 14(1):10511. PubMed ID: 38714773
[TBL] [Abstract][Full Text] [Related]
9. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
Ostrow S; Egorin MJ; Hahn D; Markus S; Aisner J; Chang P; LeRoy A; Bachur NR; Wiernik PH
Cancer Treat Rep; 1981; 65(1-2):73-8. PubMed ID: 6784924
[TBL] [Abstract][Full Text] [Related]
10. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002.
Hotta K; Takigawa N; Hisamoto-Sato A; Ichihara E; Kudo K; Uchida K; Yanase-Nakamura K; Tanaka H; Kato Y; Tabata M; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2013 Nov; 43(11):1115-23. PubMed ID: 24082005
[TBL] [Abstract][Full Text] [Related]
11. Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study.
Oka T; Kimura T; Suzumura T; Yoshimoto N; Nakai T; Yamamoto N; Matsuura K; Mitsuoka S; Yoshimura N; Kudoh S; Hirata K
BMC Pharmacol Toxicol; 2014 Dec; 15():70. PubMed ID: 25472655
[TBL] [Abstract][Full Text] [Related]
12. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
13. [An early phase II trial combining cisplatin and carboplatin in advanced non-small cell lung cancer].
Yoshimura A; Yamano Y; Gemma A; Yoshimori K; Hayashihara K; Taniguchi Y; Uematsu K; Shibuya M; Kudoh S; Niitani H
Gan To Kagaku Ryoho; 1993 Mar; 20(4):503-8. PubMed ID: 8383951
[TBL] [Abstract][Full Text] [Related]
14. Hydration with magnesium and mannitol without furosemide prevents the nephrotoxicity induced by cisplatin and pemetrexed in patients with advanced non-small cell lung cancer.
Muraki K; Koyama R; Honma Y; Yagishita S; Shukuya T; Ohashi R; Takahashi F; Kido K; Iwakami S; Sasaki S; Iwase A; Takahashi K
J Thorac Dis; 2012 Dec; 4(6):562-8. PubMed ID: 23205279
[TBL] [Abstract][Full Text] [Related]
15. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
[TBL] [Abstract][Full Text] [Related]
16. [Early phase II study of FK352 in cisplatin-induced nephropathy. Niigata Prefecture FK352 Study Group].
Yoshizawa H; Suzuki E; Arakawa M
Gan To Kagaku Ryoho; 1998 Nov; 25(13):2085-94. PubMed ID: 9838911
[TBL] [Abstract][Full Text] [Related]
17. Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review.
Sikking C; Niggebrugge-Mentink KL; van der Sman ASE; Smit RHP; Bouman-Wammes EW; Beex-Oosterhuis MM; van Kesteren C
Oncologist; 2024 Feb; 29(2):e173-e186. PubMed ID: 37995306
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.
Crona DJ; Faso A; Nishijima TF; McGraw KA; Galsky MD; Milowsky MI
Oncologist; 2017 May; 22(5):609-619. PubMed ID: 28438887
[TBL] [Abstract][Full Text] [Related]
19. Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.
Ninomiya K; Hotta K; Hisamoto-Sato A; Ichihara E; Gotoda H; Morichika D; Tamura T; Kayatani H; Minami D; Kubo T; Tabata M; Tanimoto M; Kiura K
Int J Clin Oncol; 2016 Feb; 21(1):81-7. PubMed ID: 26093520
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity.
Fukushima K; Okada A; Oe H; Hirasaki M; Hamori M; Nishimura A; Shibata N; Sugioka N
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):193-203. PubMed ID: 28913815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
